Registration Dossier

Toxicological information

Carcinogenicity

Currently viewing:

Administrative data

Description of key information

According to Column 2 of REACH Annex X, a carcinogenicity study may be required if the substance has a widespread dispersive use or there is evidence of frequent or long-term human exposure and the substance is classified as mutagen category 3 or there is evidence from the repeated dose study(ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions.  Based on the available data, tungsten dioxide would not classify as a mutagen.  No hyperplasia and/or pre-neoplastic lesions were identified in a 28-day repeated dose inhalation toxicity study on TBO, which will be used for read across. Therefore, a carcinogenicity study is not required for the registration under REACH.

Key value for chemical safety assessment

Carcinogenicity: via oral route

Link to relevant study records
Reference
Endpoint:
carcinogenicity: oral
Data waiving:
other justification
Justification for data waiving:
other:
Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via inhalation route

Link to relevant study records
Reference
Endpoint:
carcinogenicity: oral
Data waiving:
other justification
Justification for data waiving:
other:
Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via dermal route

Link to relevant study records
Reference
Endpoint:
carcinogenicity: oral
Data waiving:
other justification
Justification for data waiving:
other:
Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

Justification for classification or non-classification

No carcinogenicity data are available for tungsten dioxide. Therefore, classification cannot be made due to lack of data.